SCHEMBL3663529

SCHEMBL3663529

O=C1CC(=O)c2c(I)cccc21

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.52
MAPT P10636 2/20 0.52
RECQL P46063 1/20 0.52
MCL1 Q07820 1/20 0.52
RXFP1 Q9HBX9 1/20 0.52
TDP2 O95551 1/20 0.43
ALDH1A1 P00352 3/20 0.39
HPGD P15428 3/20 0.39
KDM4E B2RXH2 2/20 0.39
BCHE P06276 1/20 0.34
CES1 P23141 1/20 0.34
TYMS P04818 1/20 0.33
MAOA P21397 3/20 0.32
UCHL1 P09936 1/20 0.31
UCHL3 P15374 1/20 0.31
ECE1 P42892 1/20 0.31
MUS81 Q96NY9 1/20 0.31
MEN1 O00255 1/20 0.31
LMNA P02545 1/20 0.30
ALOX15 P16050 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13439628 0.74 MAOA (0.56) KMT2AMAPTRECQLMCL1RXFP1
SCHEMBL2821364 0.74 MAPT (0.52) KMT2AMAPTRECQLMCL1RXFP1
SCHEMBL14939549 0.74 MAPT (0.52) KMT2AMAPTRECQLMCL1RXFP1
SCHEMBL11237539 0.74 KMT2A (0.52) KMT2AMAPTRECQLMCL1RXFP1
SCHEMBL10672939 0.74 KMT2A (0.52) KMT2AMAPTRECQLMCL1RXFP1
SCHEMBL88188 0.70 CES1 (0.52) KMT2AMAPTRECQLMCL1RXFP1
SCHEMBL29353628 0.70 CES1 (0.52) KMT2AMAPTRECQLMCL1RXFP1
SCHEMBL12338444 0.70 ALDH1A1 (0.59) KMT2AMAPTRECQLMCL1RXFP1
SCHEMBL21090481 0.69 MAPT (0.47) KMT2AMAPTRECQLMCL1RXFP1
SCHEMBL16521619 0.68 MAPT (0.46) KMT2AMAPTRECQLMCL1RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2155680-B1 INDANONE DERIVATIVES THAT INHIBIT PROLYL HYDROXYLASE AMGEN INC (US) 2013-12-04 EP disclosed
EP-2155680-A1 INDANONE DERIVATIVES THAT INHIBIT PROLYL HYDROXYLASE Amgen, Inc (US) 2010-02-24 EP disclosed
US-7569726-B2 Indanone derivatives that inhibit prolyl hydroxylase AMGEN INC. (US) 2009-08-04 US disclosed
US-20090088475-A1 Indanone derivatives that inhibit prolyl hydroxylase AMGEN INC. (US) 2009-04-02 US disclosed
WO-2008130508-A1 INDANONE DERIVATIVES THAT INHIBIT PROLYL HYDROXYLASE AMGEN INC. (US) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088475-A1 Indanone derivatives that inhibit prolyl hydroxylase HIF1AN, EGLN3, EGLN2 KMT2A 1192/4885MAPT 3874/4885RECQL 3446/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.